Optune is the first
FDA-approved therapy in more than a decade to demonstrate statistically
significant extension of survival in newly diagnosed glioblastoma patients
The EF-14 trial
achieved statistically significant extension of both progression-free survival
and overall survival in newly diagnosed glioblastoma with a 50% increase in the
number of patients alive two-years after starting treatment when treated with TTFields
in combination with temozolomide as compared to temozolomide alone
ST. HELIER, Jersey,
Oct 6 (Bernama-BUSINESS WIRE) -- Novocure (NASDAQ:
NVCR) announced today that the U.S. Food and Drug Administration (FDA) has
approved Optune in combination with temozolomide for the treatment of adult
patients with newly diagnosed glioblastoma (GBM). Optune is a portable,
non-invasive device that delivers low-intensity, intermediate frequency,
alternating electric fields – referred to as Tumor Treating Fields (TTFields) –
that inhibit cancer cell replication and cause cancer cell death.
No comments:
Post a Comment